William Blair started Envista with an Outperform rating.

Morgan Stanley analyst Erin Wright downgraded Envista to Equal Weight from Overweight with a price target of $21, down from $33. While the shares have come under pressure and investor expectations are not overly high, there is further downside risk for Envista in a "lackluster" dental market with softer practice visit volumes amid a transitioning C-Suite, the analyst tells investors in a research note. The firm cut estimates to reflect slower organic revenue growth on weak demand and continuing share loss as well as EBITDA margin degradation. It says limited visibility on the company's path forward also contributes to the downgrade.